On Tuesday, Shares of Pfizer Inc. (NYSE:PFE), gained 1.26% to $32.83.
Pfizer appears to have finally turned the corner and put the worst of its patent exclusivity issues in the rearview mirror. The loss of key patents covering cholesterol-fighting juggernaut Lipitor and anti-inflammatory drug Celebrex packed some unwanted punishment to Pfizer’s top and bottom lines. However, in each of the past three quarters, Pfizer has delivered operational growth once the effects of currency fluctuations, divestments, and acquisitions are accounted for, according to Motley Fool.
The big reason Pfizer was able to grow its business was the outstanding performance of a few key drugs. The launch of metastatic breast cancer drug Ibrance in February following its approval by the Food and Drug Administration was a big spark. Sales of Ibrance totaled $230 million in the third quarter — just its second full quarter of sales. The pill, which essentially doubled progression-free survival for advanced breast cancer patients who are HER2-negative and estrogen-receptor positive and added more than four months to median survival relative to the placebo, looks well on its way to blockbuster status in 2016. Motley Fool Reports
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments.
Shares of Fitbit Inc. (NYSE:FIT), declined -1.71% to $29.35, during its last trading session.
Fitbit (NYSE:FIT)‘s stock had its “hold” rating reiterated by equities research analysts at Dougherty & Co in a report released on Tuesday, Analyst Ratings.Net reports.
In related news, EVP Andy Missan sold 88,500 shares of the firm’s stock in a transaction on Wednesday, November 18th. The stock was sold at an average price of $28.13, for a total transaction of $2,489,505.00. The transaction was revealed in a filing with the SEC, which is accessible through the SEC website.
Fitbit Inc. manufactures and provides wearable fitness-tracking devices worldwide. The company makes both wrist bands and clippable devices that monitor a user’s fitness activity by tracking the calories burned or distance covered.
Finally, DDR Corp. (NYSE:DDR), ended its last trade with 1.07% gain, and closed at $17.04.
December 8, 2015 - DDR Corp. (DDR) declared its fourth quarter 2015 Preferred Class J stock dividend of $0.406250 per depositary share and Preferred Class K stock dividend of $0.39063 per depositary share.
Each Class J depositary share is equal to one-twentieth of a share of DDR’s 6.50% Class J Cumulative Redeemable Preferred Stock. The declared Preferred Class J dividend covers the period starting October 15, 2015 and ending January 14, 2016. The declared Preferred Class J Dividend is payable January 15, 2016 to shareholders of record at the close of business on December 31, 2015.
Each Class K depositary share is equal to one-twentieth of a share of DDR’s 6.25% Class K Cumulative Redeemable Preferred Stock. The declared Preferred Class K dividend covers the period starting October 15, 2015 and ending January 14, 2016. The declared Preferred Class K Dividend is payable January 15, 2016 to shareholders of record at the close of business on December 31, 2015.
DDR Corp. is an equity real estate investment trust. It invests in the real estate markets of the United States and Puerto Rico. The firm is in the business of acquiring, owning, developing, redeveloping, expanding, leasing and managing shopping centers. It formerly known as Developers Diversified Realty Corp. DDR Corp is based in Beachwood, Ohio.
